

# Investor Presentation

---

Singular Research's Las Vegas Invitational Conference

June 15, 2026

# Safe Harbor Statement

This presentation and webcast contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek's future financial performance, including growth and business strategies, product and operational plans, and any expectations or assumptions thereto; the forecasted cell analysis market size and Cytek's market opportunities; Cytek's anticipated 2026 growth drivers; and Cytek's potential for sustainable growth and profitability. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. All statements other than statements of historical facts are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" or the negatives of these terms or variation of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, without limitation, global geopolitical, economic and market conditions; Cytek's ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek's ability to evaluate its prospects for future viability and predict future performance; Cytek's ability to accurately forecast customer demand and adoption of its products; Cytek's ability to recognize the anticipated benefits of collaborations; Cytek's dependence on certain sole and single source suppliers; competition; market acceptance of Cytek's current and potential products; Cytek's ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek's ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek's ability to increase penetration in its existing markets and expand into adjacent markets; Cytek's ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek's ability to successfully develop and introduce new products; Cytek's ability to maintain, protect and enhance its intellectual property; Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. Information on these and additional risks and uncertainties and other information affecting Cytek's business and operating results is contained in Cytek's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the Securities and Exchange Commission (the "SEC") on May 7, 2026, and other filings Cytek makes with the SEC from time to time. Unless otherwise indicated, these forward-looking statements speak only as of the date hereof. Except as required by applicable law, Cytek does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Cytek, the Cytek logo, Cytek Aurora, Cytek Aurora Evo, Cytek Borealis, Northern Lights, Full Spectrum Profiling, FSP, Guava, Muse, Amnis, Tonbo, DxP Athena, ESP, and cFluor are trademarks of Cytek Biosciences, Inc. Other trademarks appearing in this presentation are the property of their respective holders.

# Empowering scientific communities with leading cell analysis tools



# Cytek at a Glance

## Validated Technology Platform

**3,789**

Units Placed<sup>(1)</sup>

**>3,900**

Cytek FSP Peer-reviewed  
Publications<sup>(1)</sup>

## Broad Customer Base & Global Presence

**2,950**

Customers<sup>(2)</sup>

**76**

Countries<sup>(2)</sup>

## Strong Financial Profile



**\$44.1M**

Q1 '26 Total Revenue<sup>(1)</sup>

**\$262.2M**

Cash & Marketable  
Securities<sup>(1)</sup>

# Q1'26 Global Scale and Reach with Diversified Revenue Mix<sup>(1)</sup>



1. As of quarter ended 3/31/2026  
 2. EMEA = Europe, Middle East, & Africa  
 3. APAC = Asia-Pacific; Rest of World = Canada, Latin America, and other non-specified regions

# Flow Cytometry: An Essential Tool in Many Diverse Applications

Flow cytometry is a must-have capability underpinning key decisions for cell-based experiments, production runs, and clinical workflows.

Core Labs, CROs, and cell-therapy manufacturing groups rely on high-utilization flow cytometers that require uptime, redundancy, and harmonization.

Expanding research and advanced therapies are increasing cytometry content per study, driving higher utilization and recurring revenue pull-through of reagents and service.

Broad Applicability	
Cell + Gene Therapies	Drug Discovery
Cell line development	Translational assays
Immuno-Oncology	Genomics
Immune profiling	Clinical (inc. MRD)

**>3,900**  
Customer Peer-Reviewed Publications<sup>(1)</sup>

# FSP<sup>®</sup> Technology Enables Clinical Efficiency, Performance and Lower Costs



**Full Spectrum Profiling**

## Benefits of Cytek FSP Technology for Clinical Use

**Single Tube Increases Sensitivity and Clinical Productivity**

**Eliminates Redundant Reagents and Lowers Costs**

**Identifies Rare Populations of Abnormal Cells**

**Optimizes Use of Smaller Amounts of Specimens**

**Opens Up Opportunities for New Applications**

# Comprehensive Portfolio of Best-in-Class Cell Analysis Tools<sup>(1)</sup>

## Research Technology Instruments



Borealis<sup>(2)</sup>



Aurora Evo



Aurora



Aurora Cell Sorter



Amnis

## Solutions and Clinical



Northern Lights-CLC




Muse Micro




Reagents

## Service Business



# Large and Growing Global Cell Analysis Market Addressable by Flow Cytometry<sup>(1)</sup>



# Our Strategic Business Pillars

## Instruments

Performance

---

Intelligence

---

Harmonization

---

Reliability

---

Cost Effective

## Applications

Reagents

---

Enabler

---

Flexibility

---

Functionality

---

Recurring Revenue

## Bioinformatics

Cytek Cloud

---

Analysis / AI

---

Optimization

---

Management

---

Exchanges

## Clinical <sup>(1)</sup>

Regulatory

---

LDT

---

Menu Driven

---

AI

---

Standardization

# Reagents & Kits Driving Recurring Revenue Growth

Recurring revenue  
grew **~19% y/y** in  
Q1 2026

**Research Areas:** Immuno-  
oncology, Infectious Diseases  
and Inflammatory Diseases

**Workflows:** Drug Discovery,  
Genomics and Immunoprofiling




**Fluorochrome conjugated antibodies**  
used to identify cells of interest

Multi-color kits and panels give users  
**ready-to-use antibodies and protocols**

1- and 2-Laser 6-Color **TBNK Reagents**  
**Approved for Clinical Use in China**

CE-IVD single-color & 6-color **TBNK**  
**reagents for EU customers**

# Q1 2026 Revenue Results<sup>(1)</sup>



## Q1 2026 Commentary

Resilient performance despite persistent challenges in the life science tools industry, demonstrating technology strength and growing recurring revenue contribution

### Driven by a continuation of trends seen in 2H 2025<sup>(2)(3)</sup>:

- Return to normal growth in the US market
- Secular growth in APAC, excluding China
- Solid expansion of recurring revenue businesses WW

1. As of quarter ended 3/31/2026

2. APAC = Asia Pacific

3. WW = Worldwide

# 2026 Growth Drivers

**Growth in installed base** to drive Service growth

**Growth in Reagents** driven by expanding market share

**Flow cytometry** market growth

**Innovative** new products

**Conventional flow** cytometer replacement cycle

**Cytek Cloud** to improve workflows and utilization

**Clinical expansion** in EMEA and in China



**Thank You**